José Ramón Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
José Ramón Santos has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
Bonaventura Clotet
Infectious Diseases Department and Fundació Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol , Badalona, Catalonia , Spain
11 shared publicationsIsabel Bravo
8 shared publicationsRoger Paredes
Infectious Diseases Department and Fundació Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol , Badalona, Catalonia , Spain
8 shared publications- José Moltó
Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Germans Trias i Pujol
6 shared publications Josep M. Llibre
Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol , Badalona, Spain
5 shared publications- Roger Paredes
Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute
5 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0191225
Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19
Remdesivir inhibits the SARS-CoV-2 RNA-dependent polymerase (Nsp12). Here, we present virology analyses from the Phase 3 REDPINE trial in participants with impaired kidney function hospitalized for COVID-19 and treated with remdesivir or placebo for 5 days. Out of 243 participants enrolled and treated in the study, 42 participants had solid organ transplantation (SOT) and received immunosuppressive medication prior to and during the study. Nasopharyngeal swabs were collected at baseline and through Day 29. Virology assessments were performed using SARS-CoV-2 RT-qPCR, next-generation sequencing, and site-directed mutagenesis in a SARS-CoV-2 replicon system. Remdesivir treatment demonstrated significantly greater reductions from baseline in viral load on Day 5 and Day 7 compared with placebo ( P ≤ 0.034). In the remdesivir treatment group, participants with SOT showed significantly smaller viral load reductions from baseline on Days 5, 7, and 14 compared with participants without SOT (all P < 0.05). Mathematical modeling of viral load kinetics in participants with kidney transplants predicted a >13-day faster time to viral load decline by extending the remdesivir treatment duration from 5 days to 10 days. In four participants treated with remdesivir, emergent substitutions in Nsp12 (E136V, M794I, and C799F) with low-level reduced in vitro susceptibility to remdesivir (≤3.4 fold change in half-maximal effective concentration) were observed 9 days after cessation of remdesivir treatment. Three of the four participants had undergone SOT. Overall, remdesivir demonstrated antiviral activity in participants with impaired kidney function, with delayed viral clearance in SOT recipients and rare posttreatment emergence of Nsp12 substitutions that confer low-level reduced susceptibility to remdesivir. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04745351 ; EudraCT registration no. 2020-005416-22.
- 5 August 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0191225
Open AccessVirologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19
Remdesivir inhibits the SARS-CoV-2 RNA-dependent polymerase (Nsp12). Here, we present virology analyses from the Phase 3 REDPINE trial in participants with impaired kidney function hospitalized for COVID-19 and treated with remdesivir or placebo for 5 days. Out of 243 participants enrolled and treated in the study, 42 participants had solid organ transplantation (SOT) and received immunosuppressive medication prior to and during the study. Nasopharyngeal swabs were collected at baseline and through Day 29. Virology assessments were performed using SARS-CoV-2 RT-qPCR, next-generation sequencing, and site-directed mutagenesis in a SARS-CoV-2 replicon system. Remdesivir treatment demonstrated significantly greater reductions from baseline in viral load on Day 5 and Day 7 compared with placebo ( P ≤ 0.034). In the remdesivir treatment group, participants with SOT showed significantly smaller viral load reductions from baseline on Days 5, 7, and 14 compared with participants without SOT (all P < 0.05). Mathematical modeling of viral load kinetics in participants with kidney transplants predicted a >13-day faster time to viral load decline by extending the remdesivir treatment duration from 5 days to 10 days. In four participants treated with remdesivir, emergent substitutions in Nsp12 (E136V, M794I, and C799F) with low-level reduced in vitro susceptibility to remdesivir (≤3.4 fold change in half-maximal effective concentration) were observed 9 days after cessation of remdesivir treatment. Three of the four participants had undergone SOT. Overall, remdesivir demonstrated antiviral activity in participants with impaired kidney function, with delayed viral clearance in SOT recipients and rare posttreatment emergence of Nsp12 substitutions that confer low-level reduced susceptibility to remdesivir. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04745351 ; EudraCT registration no. 2020-005416-22.
- Open Access
- 3 August 2026
- Published by Elsevier in SSRN Electronic Journal
Long COVID Lacks a Discrete Biomarker Signature Despite Immune, Endothelial and Viral Alterations
Background: Long COVID (LC) is characterized by persistent and, often, disabling symptoms, yet its biological basis remains unclear. Multiple mechanisms, including immune dysregulation, endothelial dysfunction, and viral persistence, have been proposed, although it is unknown whether these define distinct biological subtypes or overlapping processes.Methods: We conducted a cross-sectional analysis of 314 unvaccinated individuals, including 141 people with long COVID (PWLC), 99 COVID-19-recovered controls (both groups sampled a median of 8 months after primary SARS-CoV-2 infection), and 74 uninfected participants. Circulating immune and endothelial biomarkers were quantified, and viral persistence was assessed by plasma SARS-CoV-2 RNA detection. Herpesviruses reactivation and SARS-CoV-2 humoral responses were also evaluated. Associations with symptom persistence were analyzed using multivariable models and machine learning approaches.Findings: Most soluble biomarker differences primarily distinguished previously infected individuals from uninfected controls rather than PWLC from recovered participants. Increased IL-1 receptor antagonist (IL-1RA) levels, together with reduced IL-1β/IL-1RA ratios, were the immune alterations most strongly associated with LC, while P-selectin was the endothelial marker most consistently linked to symptom persistence. Global biomarker profiles overlapped across groups and showed limited classification performance. Plasma SARS-CoV-2 RNA was detected in a minority of participants in both PWLC and recovered individuals, although PWLC showed lower Ct values and viral RNA was repeatedly associated with persistent symptoms. Epstein-Barr virus reactivation signatures were increased in PWLC, whereas SARS-CoV-2-specific antibody levels were comparable between groups.Interpretation: LC may arise from overlapping immune, endothelial, and viral perturbations rather than discrete biomarker-defined subtypes.
- 3 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLong COVID Lacks a Discrete Biomarker Signature Despite Immune, Endothelial and Viral Alterations
Background: Long COVID (LC) is characterized by persistent and, often, disabling symptoms, yet its biological basis remains unclear. Multiple mechanisms, including immune dysregulation, endothelial dysfunction, and viral persistence, have been proposed, although it is unknown whether these define distinct biological subtypes or overlapping processes.Methods: We conducted a cross-sectional analysis of 314 unvaccinated individuals, including 141 people with long COVID (PWLC), 99 COVID-19-recovered controls (both groups sampled a median of 8 months after primary SARS-CoV-2 infection), and 74 uninfected participants. Circulating immune and endothelial biomarkers were quantified, and viral persistence was assessed by plasma SARS-CoV-2 RNA detection. Herpesviruses reactivation and SARS-CoV-2 humoral responses were also evaluated. Associations with symptom persistence were analyzed using multivariable models and machine learning approaches.Findings: Most soluble biomarker differences primarily distinguished previously infected individuals from uninfected controls rather than PWLC from recovered participants. Increased IL-1 receptor antagonist (IL-1RA) levels, together with reduced IL-1β/IL-1RA ratios, were the immune alterations most strongly associated with LC, while P-selectin was the endothelial marker most consistently linked to symptom persistence. Global biomarker profiles overlapped across groups and showed limited classification performance. Plasma SARS-CoV-2 RNA was detected in a minority of participants in both PWLC and recovered individuals, although PWLC showed lower Ct values and viral RNA was repeatedly associated with persistent symptoms. Epstein-Barr virus reactivation signatures were increased in PWLC, whereas SARS-CoV-2-specific antibody levels were comparable between groups.Interpretation: LC may arise from overlapping immune, endothelial, and viral perturbations rather than discrete biomarker-defined subtypes.
- Open Access
Identification of Clinical and Genomic Features Associated with SARS-CoV-2 Reinfections
Although SARS-CoV-2 reinfections remain a concern for healthcare systems worldwide, the factors driving them are still not fully understood. In this study, we examined data for 3303 individuals who experienced two SARS-CoV-2 infections between March 2020 and May 2022 from both clinical and viral genomics perspectives. Our findings indicate that viral evolution was the primary driver of reinfection. However, chronic conditions were common among reinfected individuals, including those under 26 years old, suggesting that the presence of underlying and/or chronic conditions increases susceptibility to reinfection. The median time elapsed between infections was one year, often coinciding with the emergence of new variants. While vaccination showed only a limited protective effect against reinfection, it drastically decreased the hospitalization rate, underscoring its role in mitigating disease severity. Our findings point to the need for more flexible vaccination strategies, especially for individuals with chronic conditions. Understanding the interactions between host factors and viral evolution is critical to strengthening prevention strategies and reducing the burden of reinfections and their possible long-term complications.
Open AccessIdentification of Clinical and Genomic Features Associated with SARS-CoV-2 Reinfections
Although SARS-CoV-2 reinfections remain a concern for healthcare systems worldwide, the factors driving them are still not fully understood. In this study, we examined data for 3303 individuals who experienced two SARS-CoV-2 infections between March 2020 and May 2022 from both clinical and viral genomics perspectives. Our findings indicate that viral evolution was the primary driver of reinfection. However, chronic conditions were common among reinfected individuals, including those under 26 years old, suggesting that the presence of underlying and/or chronic conditions increases susceptibility to reinfection. The median time elapsed between infections was one year, often coinciding with the emergence of new variants. While vaccination showed only a limited protective effect against reinfection, it drastically decreased the hospitalization rate, underscoring its role in mitigating disease severity. Our findings point to the need for more flexible vaccination strategies, especially for individuals with chronic conditions. Understanding the interactions between host factors and viral evolution is critical to strengthening prevention strategies and reducing the burden of reinfections and their possible long-term complications.
- 22 February 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (5) , 1193-1194
Early virological failure with cabotegravir/rilpivirine
Long-acting (LA) therapy with cabotegravir and rilpivirine administered intramuscularly every 8 weeks (cabotegravir + rilpivirine LA-2M) has been shown to be safe and effective in switch strategies for ART in persons with HIV (PWH).1 Virological failure (VF) with cabotegravir + rilpivirine LA-2M was infrequent in pivotal clinical trials,2,3 appearing in only 1.4% of all participants (23/1651) after 152 weeks of follow-up. Similar VF rates have been reproduced in implementation studies4 and real-life cohorts.5,6 HIV subtype A1/A6, preexisting rilpivirine resistance-associated mutations (RAMs), and high BMI (associated with low drug concentrations) have been identified as potential contributors to VF with cabotegravir + rilpivirine LA-2M.7 However, up to 0.5% of cases of VF in clinical trials did not meet any of these factors. Herein we present a case of VF in a PWH who was switched to cabotegravir + rilpivirine LA-2M in clinical practice. A 55-year-old cisgender male was switched from dolutegravir/abacavir/lamivudine to cabotegravir + rilpivirine LA-2M after 14 years with continued HIV-1 plasma viral load (pVL) suppression (pVL < 20 copies/mL). The subject had neither prior exposure to NNRTIs nor previous treatment interruptions or VF. Beside HIV infection, he did not have any other medical conditions and was not receiving any concomitant treatment; his BMI was 25.3 kg/m2 and the CD4+ T cell count was 780 cells/mm3. Previous genotypes and viral subtype information were not available because he had been transferred from another site. Surprisingly, four weeks (‘WK4’) after the first dose of cabotegravir + rilpivirine LA, pVL increased up to 113 046 copies/mL. VF was confirmed in a second blood sample collected 8 days later (‘4WK + 8D’), showing a pVL of 1039 copies/mL. Cabotegravir and rilpivirine concentrations in plasma were 330 and 78 ng/mL at ‘4WK’, and 2512 and 179 ng/mL at ‘4WK + 8D’. HIV-1 genotypic tests at ‘WK4’ and ‘WK4 + 8’ revealed B HIV-1 subtype together with the presence of E138A and V179I mutations in the RT gene, related to resistance to rilpivirine. No RAMs in the protease or in the integrase regions were detected (see Table 1). ART was modified to darunavir/cobicistat/emtricitabine/tenofovir alafenamide, achieving successful virological suppression 4 weeks later. Due to gastrointestinal complaints, the patient requested to revert to his previous ART with dolutegravir/abacavir/lamivudine and the pVL remained <20 copies/mL.
- 22 February 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (5) , 1193-1194
Early virological failure with cabotegravir/rilpivirine
Long-acting (LA) therapy with cabotegravir and rilpivirine administered intramuscularly every 8 weeks (cabotegravir + rilpivirine LA-2M) has been shown to be safe and effective in switch strategies for ART in persons with HIV (PWH).1 Virological failure (VF) with cabotegravir + rilpivirine LA-2M was infrequent in pivotal clinical trials,2,3 appearing in only 1.4% of all participants (23/1651) after 152 weeks of follow-up. Similar VF rates have been reproduced in implementation studies4 and real-life cohorts.5,6 HIV subtype A1/A6, preexisting rilpivirine resistance-associated mutations (RAMs), and high BMI (associated with low drug concentrations) have been identified as potential contributors to VF with cabotegravir + rilpivirine LA-2M.7 However, up to 0.5% of cases of VF in clinical trials did not meet any of these factors. Herein we present a case of VF in a PWH who was switched to cabotegravir + rilpivirine LA-2M in clinical practice. A 55-year-old cisgender male was switched from dolutegravir/abacavir/lamivudine to cabotegravir + rilpivirine LA-2M after 14 years with continued HIV-1 plasma viral load (pVL) suppression (pVL < 20 copies/mL). The subject had neither prior exposure to NNRTIs nor previous treatment interruptions or VF. Beside HIV infection, he did not have any other medical conditions and was not receiving any concomitant treatment; his BMI was 25.3 kg/m2 and the CD4+ T cell count was 780 cells/mm3. Previous genotypes and viral subtype information were not available because he had been transferred from another site. Surprisingly, four weeks (‘WK4’) after the first dose of cabotegravir + rilpivirine LA, pVL increased up to 113 046 copies/mL. VF was confirmed in a second blood sample collected 8 days later (‘4WK + 8D’), showing a pVL of 1039 copies/mL. Cabotegravir and rilpivirine concentrations in plasma were 330 and 78 ng/mL at ‘4WK’, and 2512 and 179 ng/mL at ‘4WK + 8D’. HIV-1 genotypic tests at ‘WK4’ and ‘WK4 + 8’ revealed B HIV-1 subtype together with the presence of E138A and V179I mutations in the RT gene, related to resistance to rilpivirine. No RAMs in the protease or in the integrase regions were detected (see Table 1). ART was modified to darunavir/cobicistat/emtricitabine/tenofovir alafenamide, achieving successful virological suppression 4 weeks later. Due to gastrointestinal complaints, the patient requested to revert to his previous ART with dolutegravir/abacavir/lamivudine and the pVL remained <20 copies/mL.
- Open Access
- 31 October 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (11) , ofad542
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
Suppressed patients with drug-resistant HIV-1 require effective and simple antiretroviral therapy to maintain treatment adherence and viral suppression. This randomized, open-label, noninferiority, multicenter pilot study involved HIV-infected adults who met the following criteria: confirmed HIV-1 RNA P = .159) with an estimated difference of −8.7 (95% CI, −22.72 to 5.14). Only 2 (4.5%) in the SOC group experienced virologic failure, and 3 participants from the 2D group experienced adverse events leading to treatment discontinuation. In suppressed patients with at least 2 resistant antiretroviral classes, noninferiority could not be demonstrated by fully active DRV/c plus DTG. Nevertheless, there were no unexpected adverse events or virologic failure. DRV/c plus DTG may be considered a once-daily therapy option only for well-selected patients. Clinical Trials Registration. ClinicalTrials.gov (NCT03683524).
- 31 October 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (11) , ofad542
Open AccessA Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
Suppressed patients with drug-resistant HIV-1 require effective and simple antiretroviral therapy to maintain treatment adherence and viral suppression. This randomized, open-label, noninferiority, multicenter pilot study involved HIV-infected adults who met the following criteria: confirmed HIV-1 RNA P = .159) with an estimated difference of −8.7 (95% CI, −22.72 to 5.14). Only 2 (4.5%) in the SOC group experienced virologic failure, and 3 participants from the 2D group experienced adverse events leading to treatment discontinuation. In suppressed patients with at least 2 resistant antiretroviral classes, noninferiority could not be demonstrated by fully active DRV/c plus DTG. Nevertheless, there were no unexpected adverse events or virologic failure. DRV/c plus DTG may be considered a once-daily therapy option only for well-selected patients. Clinical Trials Registration. ClinicalTrials.gov (NCT03683524).
- Open Access
- 26 June 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1187999
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Introduction: Second-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients.Methods: Real-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naïve patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) ≥200 copies/mL at 24 weeks or as a single determination of VL ≥1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated.Results: Virological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naïve patients with CD4+ nadir <100 cells/μL were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles.Discussion: Whereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available.
- 26 June 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1187999
Open AccessEffectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Introduction: Second-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients.Methods: Real-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naïve patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) ≥200 copies/mL at 24 weeks or as a single determination of VL ≥1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated.Results: Virological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naïve patients with CD4+ nadir <100 cells/μL were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles.Discussion: Whereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available.
- Open Access
- 7 August 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 31, 52-62
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study
- 7 August 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 31, 52-62
Open AccessVirological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study
- 15 September 2020
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (12) , 3517-3524
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping
Background: Transmission of resistance mutations to integrase strand transfer inhibitors (INSTIs) in HIV-infected patients may compromise the efficacy of first-line antiretroviral regimens currently recommended worldwide. Continued surveillance of transmitted drug resistance (TDR) is thus warranted.Objectives: We evaluated the rates and effects on virological outcomes of TDR in a 96 week prospective multicentre cohort study of ART-naive HIV-1-infected subjects initiating INSTI-based ART in Spain between April 2015 and December 2016.Methods: Pre-ART plasma samples were genotyped for integrase, protease and reverse transcriptase resistance using Sanger population sequencing or MiSeq™ using a ≥ 20% mutant sensitivity cut-off. Those present at 1%–19% of the virus population were considered to be low-frequency variants.Results: From a total of 214 available samples, 173 (80.8%), 210 (98.1%) and 214 (100.0%) were successfully amplified for integrase, reverse transcriptase and protease genes, respectively. Using a Sanger-like cut-off, the overall prevalence of any TDR, INSTI-, NRTI-, NNRTI- and protease inhibitor (PI)-associated mutations was 13.1%, 1.7%, 3.8%, 7.1% and 0.9%, respectively. Only three (1.7%) subjects had INSTI TDR (R263K, E138K and G163R), while minority variants with integrase TDR were detected in 9.6% of subjects. There were no virological failures during 96 weeks of follow-up in subjects harbouring TDR as majority variants.Conclusions: Transmitted INSTI resistance remains rare in Spain and, to date, is not associated with virological failure to first-line INSTI-based regimens.
- 15 September 2020
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (12) , 3517-3524
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping
Background: Transmission of resistance mutations to integrase strand transfer inhibitors (INSTIs) in HIV-infected patients may compromise the efficacy of first-line antiretroviral regimens currently recommended worldwide. Continued surveillance of transmitted drug resistance (TDR) is thus warranted.Objectives: We evaluated the rates and effects on virological outcomes of TDR in a 96 week prospective multicentre cohort study of ART-naive HIV-1-infected subjects initiating INSTI-based ART in Spain between April 2015 and December 2016.Methods: Pre-ART plasma samples were genotyped for integrase, protease and reverse transcriptase resistance using Sanger population sequencing or MiSeq™ using a ≥ 20% mutant sensitivity cut-off. Those present at 1%–19% of the virus population were considered to be low-frequency variants.Results: From a total of 214 available samples, 173 (80.8%), 210 (98.1%) and 214 (100.0%) were successfully amplified for integrase, reverse transcriptase and protease genes, respectively. Using a Sanger-like cut-off, the overall prevalence of any TDR, INSTI-, NRTI-, NNRTI- and protease inhibitor (PI)-associated mutations was 13.1%, 1.7%, 3.8%, 7.1% and 0.9%, respectively. Only three (1.7%) subjects had INSTI TDR (R263K, E138K and G163R), while minority variants with integrase TDR were detected in 9.6% of subjects. There were no virological failures during 96 weeks of follow-up in subjects harbouring TDR as majority variants.Conclusions: Transmitted INSTI resistance remains rare in Spain and, to date, is not associated with virological failure to first-line INSTI-based regimens.
- Open Access
- 17 June 2020
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (9) , 2535-2546
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
Background: Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene.Methods: From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecular modelling information to detect conformational changes in the Gag region.Results: All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R and R286K (P < 0.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir susceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug susceptibility and virus replicative capacity.Conclusions: Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.
- 17 June 2020
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (9) , 2535-2546
Open AccessHIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
Background: Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene.Methods: From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. We sequenced the HIV-1 Gag-protease region and generated clonal virus from plasma samples. We characterized phenotypically clonal variants in terms of replicative capacity and susceptibility to PIs. Also, we used VESPA to identify signature mutations and 3D molecular modelling information to detect conformational changes in the Gag region.Results: All subjects analysed harboured Gag-associated polymorphisms in the absence of resistance mutations in the protease gene. Most Gag changes occurred outside Gag cleavage sites. VESPA analyses identified K95R and R286K (P < 0.01) as signature mutations in Gag present at VF. In one out of four patients with clonal analysis available, we identified clonal variants with high replicative capacity and 8- to 13-fold reduction in darunavir susceptibility. These clonal variants harboured K95R, R286K and additional mutations in Gag. Low susceptibility to darunavir was dependent on the Gag sequence context. All other clonal variants analysed preserved drug susceptibility and virus replicative capacity.Conclusions: Gag mutations may reduce darunavir susceptibility in the absence of protease mutations while preserving viral fitness. This effect is Gag-sequence context dependent and may occur during boosted PI failure.
- Open Access
- 28 January 2020
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-4
Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report
Background: Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD). Case presentation: A 53-year-old woman with HIV/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular hemodialyis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125 mg twice daily) and tadalafil (20 mg once daily) for PAH and antiretroviral treatment (cART) including darunavir/cobicistat (800/150 mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and darunavir/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her clinical condition. Pre- and postdialyzer cocentrations of ambrisentan in plasma were determined and hemodialysis extraction ratio for ambrisentan was 2%. Conclusions: Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis.
- 28 January 2020
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-4
Open AccessAmbrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report
Background: Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD). Case presentation: A 53-year-old woman with HIV/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular hemodialyis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125 mg twice daily) and tadalafil (20 mg once daily) for PAH and antiretroviral treatment (cART) including darunavir/cobicistat (800/150 mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and darunavir/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her clinical condition. Pre- and postdialyzer cocentrations of ambrisentan in plasma were determined and hemodialysis extraction ratio for ambrisentan was 2%. Conclusions: Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis.